Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design

November 09, 2009

DURHAM, N.C. - A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

"Our study clearly showed that we've been overlooking a very important component of antibody function," says S. Munir Alam, Ph.D., an associate professor of medicine at Duke University Medical Center and lead author of the paper appearing in the Proceedings of the National Academy of Sciences.

Alam, a member of the Duke Human Vaccine Institute and study senior author Bing Chen, Ph.D., assistant professor of pediatrics, Harvard Medical School and Children's Hospital Boston, studied two potentially powerful antibodies against HIV, 2F5 and 4E10. Both of these are rare, broadly neutralizing antibodies, meaning that they can block a number of different strains of the HIV virus. They accomplish that by binding to the "Achilles heel" of the virus - the so-called outer coat membrane proximal region - a part of the outer protein coating next to the viral membrane that opens up and is exposed to the antibodies for just a few minutes during the process of cell fusion and infection.

But the problem for infection control is that such powerful antibodies are rare in HIV infection, and current experimental vaccines have been unable to generate such antibodies. In addition, the window of opportunity for such antibodies to act is very narrow.

"The target region on the virus is only open for a few minutes - maybe 15 minutes or less," says Alam. "Unless the antibody is very close by and ready to home in on it, it won't work. That means our goal has to be the creation of a vaccine that can induce a whole lot more of these antibodies and have them ready to go at the earliest moment of infection."

"Fortunately, our study gave us new information that will help us accomplish this goal," says Chen.

The 2F5 and 4E10 antibodies have unusually long, loopy protein segments that are hydrophobic, meaning that they are attracted to lipids. The researchers found that successful docking of the antibody to the HIV outer coat membrane region required antibody attachment to HIV's membrane, which contains lipid.

"This two-step mechanism, not previously appreciated, might extend to antibodies that protect against other viruses," says co-author Stephen Harrison, Ph.D., of Harvard Medical School, Children's Hospital Boston, and the Howard Hughes Medical Institute.

The research team is already working on designing a vaccine that incorporates a lipid component. "The demonstration of the role of virion lipid reactivity in the overall function of these neutralizing antibodies has provided key insights into what the immune system may need to see to make such antibodies", says co-author and Vaccine Institute Director Barton Haynes. "New vaccine designs trials based on these observations are now ongoing in animals."
-end-
The study was funded by a Collaboration for AIDS Vaccine Discovery grant to Duke and Harvard from the Bill and Melinda Gates Foundation and grants from the National Institutes of Health.

Colleagues from Duke who contributed to the study include Moses Dennison, Hua-Xin Liao, Ruijan Zhang and Shi-Mao Xia. Additional coauthors include Marco Morelli and Sophia Rits-Volloch, from Children's Hospital Boston and Li Sun, from Xiamen Amoytop Biotech Company, Ltd., China.

Duke University Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.